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and a moderate increase in A10BD (Biguanides and sulfonamides
in combination) in 2001 (0.07) and in 2006 (1.41) in term of
DID can be seen from this analysis. Financial expenditures for
antidiabetics were (in 1996 (€9,772,000), in 2001 (€18,169,000)
and in 2006 (€26,541,000). CONCLUSION: Inseparable com-
ponents of the Slovak drug policy must be viewed realistically
with regard to the antidiabetics’ consumption. Adherence to
principles of diabetes mellitus treatment’s guidelines lead to fun-
damental short and long term ﬁnancial savings within health care
systems.
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OBJECTIVE: In the treatment of type 2 diabetes (T2D), achiev-
ing glucose control often requires multiple therapies. The class of
antidiabetic agents called incretin mimetics offers an alternative
mechanism to diabetes management. This work describes the
baseline demographic and clinical characteristics of a T2D popu-
lation in a primary care setting before they initiated treatment
with the incretin mimetic, exenatide. METHODS: Patients were
extracted from the General Electric (GE) electronic medical
record (EMR) database from January 1, 2000 through June 30,
2007. Patients with T2D (diagnosis, oral antidiabetic drug pre-
scription, two consecutive fasting blood glucose levels 126 mg/
dL, or A1C 7.0%) were identiﬁed, as were those with at least
one prescription for exenatide. Using these data, descriptive sta-
tistics were calculated for these populations. RESULTS: Of the
11,601 patients with a prescription for exenatide, nearly all had
T2D (96%). A total of 7425 of the patients with a prescription of
exenatide were 18 years of age and had at least 395 days of
records prior to the index date. Compared to the 510,623 T2D
patients on other treatments with these same age and records
restrictions in the GE EMR, those patients on exenatide were
signiﬁcantly heavier (204.2 lbs. vs. 244.2 lbs. (p < 0.001)) with
higher BMI (32.9 kg/m2 vs. 38.7 kg/m2 (p < 0.001)). A larger
percentage of the exenatide population was obese or extremely
obese than the population on other treatments (89% vs. 61%
(p < 0.001)). The portion of the exenatide population with base-
line A1C 9.0 was higher than that of the population on other
treatments (56% vs. 12% (p < 0.001)) and, compared to the
total, exenatide patients had signiﬁcantly higher mean A1Cs
(7.2% vs. 8.1% (p < 0.001)). CONCLUSION: These results
suggest that exenatide is being added to T2D treatment regimens
in obese patients with relatively high A1C levels to achieve better
diabetes control.
PDB68
AN ASSESSMENT OFTHE IMPACT OFTHE COVERAGE
GAP UPON MEDICARE PART D BENEFICIARIES
UTILIZING INSULIN
Skrepnek GH1, Denarie MF2, Conner C3, Forma FM3
1University of Arizona,Tucson, AZ, USA, 2IMS Health Inc, Plymouth
Meeting, PA, USA, 3Novo Nordisk Inc, Princeton, NJ, USA
OBJECTIVE: To assess the extent of, exposure to, and medica-
tion expenditure trends associated with insulin-treated patients
reaching the Medicare Part D standard beneﬁciary prescription
coverage gap (i.e., ‘doughnut hole’) and catastrophic coverage.
METHODS: Patients receiving various insulin formulations and
mixtures throughout 2006 were investigated via a prescription
transaction-level retrospective database that captured 50% of all
retail dispensing activity within the U.S. Analyses focused upon
the coverage gap and catastrophic coverage within standard ben-
eﬁciaries regarding: 1) the number of patients entering; 2) the
month of entry; and 3) medication expenditures. RESULTS:
Overall, 324,430 Medicare beneﬁciaries received an insulin
regimen in 2006, consisting of 41% dual-eligibles (n = 131,611),
32% low-income subsidiaries (n = 105,151), and 27% standard
beneﬁciaries (n = 87,668). Across all coverage groups, oral
antidiabetic agents and insulin comprised 66–72% of monthly
drug expenditures. Of those potentially being exposed to a cov-
erage gap, 46% reached the ‘doughnut hole’ (12% of all Part D
beneﬁciaries) and 12% entered catastrophic coverage (3% of all
Part D beneﬁciaries). Among the near 55,300 standard beneﬁ-
ciaries (63% of 87,668) enrolling in Part D by March 2006,
prescription expenditures peaked in the month prior to entering
the coverage gap, followed by an immediate 20–25% drop in the
month thereafter. Decreased expenditures broadly corresponded
to a decrease in the number of diabetes agents dispensed. CON-
CLUSION: This analysis found that 46% of all insulin-treated
patients covered by the Medicare Part D standard beneﬁt (12%
of all Part D beneﬁciaries) were exposed to the coverage gap in
2006, characterized by a shifting of full ﬁnancial responsibility to
beneﬁciaries for outpatient medications. Entry was followed by a
20–25% decrease in expenditures and, more generally, in the
number of diabetes agents received. These ﬁndings warrant
continued evaluation of coverage policies and any subsequent
cost-shifting or deferrals in care that may occur, particularly for
chronic diseases.
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OBJECTIVE: Use of adjunctive insulin therapy with oral anti-
hyperglycemic agents in patients with type 2 diabetes (T2D) has
been growing in the US following demonstration in the U.K.
Prospective Diabetes Study that intensive therapy regimens
increased glycemic control and reduced microvascular complica-
tions. The primary objective in this study was to compare the
effect of analog insulin with human insulin usage on all-cause
and diabetes-attributable direct health care costs and utilization
in patients with type 2 diabetes. METHODS: Using the
MarketScan Research Database, commercially insured patients
were selected who initiated insulin therapy with analog or human
insulins during 2001–2005, had no insulin claims 12 months
prior to starting therapy, and a type 2 diabetes diagnosis during
the study period. Patients were followed 12-months from insulin
therapy initiation, and were stratiﬁed according to their therapy
as receiving analog insulin only (n = 18,205), human insulin only
(n = 7035), or both analog and human insulins (n = 5040).
Health care utilization and expenditures were compared between
treatment groups and between pre-index and post-index periods.
Generalized multi-valued propensity score weighting was used to
control for observable differences in distributions of pretreat-
ment variables among treatment groups. RESULTS: Although
mean costs for insulin and other prescriptions were lowest for
patients receiving only human insulin, mean post-index total
all-cause health care costs for analog insulin patients ($17,059)
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